ArticleScientific reports2025
Epidemiology of potential source, risk attribution of Clostridium perfringens from Egyptian broiler farms and genetic diversity of multidrug resistance strains.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular epidemiology and PFGE-based genetic diversity of Clostridium perfringens in broiler chickens from Eastern Türkiye.BMC veterinary research · 2026Article
- Glycerol monolaurate attenuates necrotic enteritis in broilers by improving gut-liver health and remodeling the gut microbiota.Journal of animal science and biotechnology · 2026Article
- Toxin genotypes and antimicrobial resistance profiles ofVeterinary world · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium perfringens induced necrotic enteritis (NE) became a persistent problem that had a major financial impact on the poultry business worldwide. Nevertheless, no prior research has assessed the related risk factors in Egyptian broiler farms. Thus, the purpose of this study is to perform an epidemiological analysis of C. perfringens occurrence, toxinotyping, and risk factors in El-Dakhlia and Damietta provinces, Egypt as well as their characteristics of antimicrobial resistance and molecular typing. From 25 broiler farms, 1100 samples were gathered. Antimicrobial resistance profiles and molecular typing were used to characterize the isolates. The findings revealed an overall prevalence of 26.3% (289/1100) from chickens' clinical samples (30.3%; 273/900) and farm environmental samples (8%; 16/200). Toxinotyping of 289 isolates showed that 165 (57.1%) isolates were C. perfringens type A, harboring only alpha toxin gene (cpa) while 124 (42.9%) isolates were C. perfringens type G, containing netB gene. The cpb2 genes were found in 66 (22.8%) isolates with the highest positive rate from dead birds. Additionally, the study found a number of possible risk variables that were substantially linked to the prevalence of C. perfringens, including location in Damietta, winter season, history of coccidia infection, use of antimicrobial growth promoters, birds older than 22 days, wet litter type, and biosecurity strategy. Univariate and multivariate analyses showed a significant association between C. perfringens infection and grower chickens (OR 2.09, 95% CI 1.05-4.21, p = 0.037) compared to starter chickens. The isolates displayed their highest resistance rate to sulfamethoxazole-trimethoprim (94.5%), erythromycin, imipenem (94.1% each), penicillin, ampicillin, streptomycin, gentamycin (90.7% each), ampicillin/sulbactam (89.9%), cefuroxime and cefepime (85.8%), nalidixic acid (85.1%), and tetracycline (78.9%). Remarkably, none of the strains were resistant to meropenem. Multidrug-resistant was observed in 94.5% strains with MAR index of 0.32-0.79. The resistance genes carried by different strains were obviously different, among which the detection rate of aminoglycoside resistance gene aphA1, was the highest (100%), followed by bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.